EYLEA (aflibercept) 8mg is added to the PBS for treating wet age-related macular degeneration (wAMD) and diabetic macular oedema (DMO).
The new formulation, containing four times the molar dose of the original, reduces injection frequency without compromising safety or effectiveness.
Patients will require just three initial monthly injections, followed by extended dosing intervals of eight to 16 weeks.
Studies show most wAMD and DMO patients can be managed with three- to four-monthly injections.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Oct 24
